Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 120 entries
Sorted by: Best Match Show Resources per page
A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis.

Rheumatology international

Chung TT, Ko HJ, Lau CS, Chung HY.
PMID: 32318800
Rheumatol Int. 2020 Jun;40(6):983-990. doi: 10.1007/s00296-020-04583-8. Epub 2020 Apr 21.

Tuberculosis (TB) is an important preventable infection in patients with rheumatoid arthritis (RA). To determine the risk of TB in patients with RA by comparing with those with non-specific back pain (NSBP), and to identify the risk factors in...

Cite
Chung TT, Ko HJ, Lau CS, et al. A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis. Rheumatol Int. 2020;40(6):983-990doi: 10.1007/s00296-020-04583-8.
Chung, T. T., Ko, H. J., Lau, C. S., & Chung, H. Y. (2020). A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis. Rheumatology international, 40(6), 983-990. https://doi.org/10.1007/s00296-020-04583-8
Chung, Tin Tsun, et al. "A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis." Rheumatology international vol. 40,6 (2020): 983-990. doi: https://doi.org/10.1007/s00296-020-04583-8
Chung TT, Ko HJ, Lau CS, Chung HY. A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis. Rheumatol Int. 2020 Jun;40(6):983-990. doi: 10.1007/s00296-020-04583-8. Epub 2020 Apr 21. PMID: 32318800.
Copy Download .nbib Format: NLM
Biogenic Selenium Nanoparticles: Potential Solution to Oxidative Stress Mediated Inflammation in Rheumatoid Arthritis and Associated Complications.

Nanomaterials (Basel, Switzerland)

Rehman A, John P, Bhatti A.
PMID: 34443836
Nanomaterials (Basel). 2021 Aug 05;11(8). doi: 10.3390/nano11082005.

Rheumatoid arthritis (RA) is a common chronic inflammation-mediated disorder having systematic complications. RA triggers a self-directed inflammatory and immunological cascade that culminates in joint destruction. Though a range of treatment options are available, none of them are without adverse...

Cite
Rehman A, John P, Bhatti A. Biogenic Selenium Nanoparticles: Potential Solution to Oxidative Stress Mediated Inflammation in Rheumatoid Arthritis and Associated Complications. Nanomaterials (Basel). 2021;11(8)doi: 10.3390/nano11082005.
Rehman, A., John, P., & Bhatti, A. (2021). Biogenic Selenium Nanoparticles: Potential Solution to Oxidative Stress Mediated Inflammation in Rheumatoid Arthritis and Associated Complications. Nanomaterials (Basel, Switzerland), 11(8), . https://doi.org/10.3390/nano11082005
Rehman, Ayesha, et al. "Biogenic Selenium Nanoparticles: Potential Solution to Oxidative Stress Mediated Inflammation in Rheumatoid Arthritis and Associated Complications." Nanomaterials (Basel, Switzerland) vol. 11,8 (2021). doi: https://doi.org/10.3390/nano11082005
Rehman A, John P, Bhatti A. Biogenic Selenium Nanoparticles: Potential Solution to Oxidative Stress Mediated Inflammation in Rheumatoid Arthritis and Associated Complications. Nanomaterials (Basel). 2021 Aug 05;11(8). doi: 10.3390/nano11082005. PMID: 34443836; PMCID: PMC8401564.
Copy Download .nbib Format: NLM
The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data.

Rheumatology and therapy

Tang W, Khalili L, Giles J, Gartshteyn Y, Kapoor T, Guo C, Chen T, Theodore D, Askanase A.
PMID: 34028704
Rheumatol Ther. 2021 Jun;8(2):681-691. doi: 10.1007/s40744-021-00315-x. Epub 2021 May 24.

Since the first outbreak of Coronavirus Disease-2019 (COVID-19) in January 2020, the medical community has been pursuing effective countermeasures. Early in the pandemic, several small clinical and in vitro studies from France and China reported on the efficacy of...

Cite
Tang W, Khalili L, Giles J, et al. The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. Rheumatol Ther. 2021;8(2):681-691doi: 10.1007/s40744-021-00315-x.
Tang, W., Khalili, L., Giles, J., Gartshteyn, Y., Kapoor, T., Guo, C., Chen, T., Theodore, D., & Askanase, A. (2021). The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. Rheumatology and therapy, 8(2), 681-691. https://doi.org/10.1007/s40744-021-00315-x
Tang, Wei, et al. "The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data." Rheumatology and therapy vol. 8,2 (2021): 681-691. doi: https://doi.org/10.1007/s40744-021-00315-x
Tang W, Khalili L, Giles J, Gartshteyn Y, Kapoor T, Guo C, Chen T, Theodore D, Askanase A. The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. Rheumatol Ther. 2021 Jun;8(2):681-691. doi: 10.1007/s40744-021-00315-x. Epub 2021 May 24. PMID: 34028704; PMCID: PMC8142615.
Copy Download .nbib Format: NLM
Thyroid Disease in Lupus: An Updated Review.

ACR open rheumatology

Klionsky Y, Antonelli M.
PMID: 32043833
ACR Open Rheumatol. 2020 Feb;2(2):74-78. doi: 10.1002/acr2.11105. Epub 2020 Jan 06.

In the following review, we seek to provide an overview of the current understanding of various thyroid manifestations affecting patients with systemic lupus erythematosus (SLE), including topics ranging from thyroid-related complications to SLE in pregnancy. Autoimmune diseases tend to...

Cite
Klionsky Y, Antonelli M. Thyroid Disease in Lupus: An Updated Review. ACR Open Rheumatol. 2020;2(2):74-78doi: 10.1002/acr2.11105.
Klionsky, Y., & Antonelli, M. (2020). Thyroid Disease in Lupus: An Updated Review. ACR open rheumatology, 2(2), 74-78. https://doi.org/10.1002/acr2.11105
Klionsky, Yael, and Antonelli, Maria. "Thyroid Disease in Lupus: An Updated Review." ACR open rheumatology vol. 2,2 (2020): 74-78. doi: https://doi.org/10.1002/acr2.11105
Klionsky Y, Antonelli M. Thyroid Disease in Lupus: An Updated Review. ACR Open Rheumatol. 2020 Feb;2(2):74-78. doi: 10.1002/acr2.11105. Epub 2020 Jan 06. PMID: 32043833; PMCID: PMC7011406.
Copy Download .nbib Format: NLM
Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.

Annals of the rheumatic diseases

Jovani V, Calabuig I, Peral-Garrido ML, Tovar-Sugrañes E, López-González MD, Bernabeu P, Martínez A, Esteve-Vives J, León-Ramírez JM, Moreno-Perez O, Boix V, Gil J, Merino E, Vela P, Andrés M.
PMID: 32586922
Ann Rheum Dis. 2020 Jun 25; doi: 10.1136/annrheumdis-2020-218152. Epub 2020 Jun 25.

No abstract available.

Cite
Jovani V, Calabuig I, Peral-Garrido ML, et al. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218152.
Jovani, V., Calabuig, I., Peral-Garrido, M. L., Tovar-Sugrañes, E., López-González, M. D., Bernabeu, P., Martínez, A., Esteve-Vives, J., León-Ramírez, J. M., Moreno-Perez, O., Boix, V., Gil, J., Merino, E., Vela, P., & Andrés, M. (2020). Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218152
Jovani, Vega, et al. "Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218152
Jovani V, Calabuig I, Peral-Garrido ML, Tovar-Sugrañes E, López-González MD, Bernabeu P, Martínez A, Esteve-Vives J, León-Ramírez JM, Moreno-Perez O, Boix V, Gil J, Merino E, Vela P, Andrés M. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors. Ann Rheum Dis. 2020 Jun 25; doi: 10.1136/annrheumdis-2020-218152. Epub 2020 Jun 25. PMID: 32586922.
Copy Download .nbib Format: NLM
Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'.

Annals of the rheumatic diseases

Pethoe-Schramm A, Devenport J, Reiss W.
PMID: 32737114
Ann Rheum Dis. 2020 Jul 31; doi: 10.1136/annrheumdis-2020-218365. Epub 2020 Jul 31.

No abstract available.

Cite
Pethoe-Schramm A, Devenport J, Reiss W. Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218365.
Pethoe-Schramm, A., Devenport, J., & Reiss, W. (2020). Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218365
Pethoe-Schramm, Attila, et al. "Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218365
Pethoe-Schramm A, Devenport J, Reiss W. Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'. Ann Rheum Dis. 2020 Jul 31; doi: 10.1136/annrheumdis-2020-218365. Epub 2020 Jul 31. PMID: 32737114.
Copy Download .nbib Format: NLM
Correspondence on 'The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series'.

Annals of the rheumatic diseases

Watanabe R, Hashimoto M, Morinobu A.
PMID: 33144301
Ann Rheum Dis. 2020 Nov 03; doi: 10.1136/annrheumdis-2020-219270. Epub 2020 Nov 03.

No abstract available.

Cite
Watanabe R, Hashimoto M, Morinobu A. Correspondence on 'The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series'. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-219270.
Watanabe, R., Hashimoto, M., & Morinobu, A. (2020). Correspondence on 'The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series'. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-219270
Watanabe, Ryu, et al. "Correspondence on 'The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series'." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-219270
Watanabe R, Hashimoto M, Morinobu A. Correspondence on 'The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series'. Ann Rheum Dis. 2020 Nov 03; doi: 10.1136/annrheumdis-2020-219270. Epub 2020 Nov 03. PMID: 33144301.
Copy Download .nbib Format: NLM
Correspondence to: 'Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'.

Annals of the rheumatic diseases

Ma KS, Wang LT, Tsai SY.
PMID: 33028582
Ann Rheum Dis. 2020 Oct 07; doi: 10.1136/annrheumdis-2020-218704. Epub 2020 Oct 07.

No abstract available.

Cite
Ma KS, Wang LT, Tsai SY. Correspondence to: 'Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218704.
Ma, K. S., Wang, L. T., & Tsai, S. Y. (2020). Correspondence to: 'Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218704
Ma, Kevin Sheng-Kai, et al. "Correspondence to: 'Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218704
Ma KS, Wang LT, Tsai SY. Correspondence to: 'Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'. Ann Rheum Dis. 2020 Oct 07; doi: 10.1136/annrheumdis-2020-218704. Epub 2020 Oct 07. PMID: 33028582.
Copy Download .nbib Format: NLM
Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?.

Annals of the rheumatic diseases

Erre GL, Ferraccioli ES, Piga M, Mangoni A, Passiu G, Gremese E, Ferraccioli G.
PMID: 32424028
Ann Rheum Dis. 2020 May 18; doi: 10.1136/annrheumdis-2020-217828. Epub 2020 May 18.

No abstract available.

Cite
Erre GL, Ferraccioli ES, Piga M, et al. Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-217828.
Erre, G. L., Ferraccioli, E. S., Piga, M., Mangoni, A., Passiu, G., Gremese, E., & Ferraccioli, G. (2020). Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-217828
Erre, Gian Luca, et al. "Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-217828
Erre GL, Ferraccioli ES, Piga M, Mangoni A, Passiu G, Gremese E, Ferraccioli G. Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?. Ann Rheum Dis. 2020 May 18; doi: 10.1136/annrheumdis-2020-217828. Epub 2020 May 18. PMID: 32424028.
Copy Download .nbib Format: NLM
Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Azouz AA, Saleh E, Abo-Saif AA.
PMID: 32922141
Saudi Pharm J. 2020 Sep;28(9):1101-1111. doi: 10.1016/j.jsps.2020.07.011. Epub 2020 Aug 03.

Rheumatoid arthritis (RA) is an autoimmune inflammatory disease, which is accompanied by progressive joint damage and disability. The intolerability of conventional antirheumatic drugs by some patients necessitates the search for effective antirheumatic agents having better tolerability. In the current...

Cite
Azouz AA, Saleh E, Abo-Saif AA. Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway. Saudi Pharm J. 2020;28(9):1101-1111doi: 10.1016/j.jsps.2020.07.011.
Azouz, A. A., Saleh, E., & Abo-Saif, A. A. (2020). Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 28(9), 1101-1111. https://doi.org/10.1016/j.jsps.2020.07.011
Azouz, Amany A, et al. "Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 28,9 (2020): 1101-1111. doi: https://doi.org/10.1016/j.jsps.2020.07.011
Azouz AA, Saleh E, Abo-Saif AA. Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway. Saudi Pharm J. 2020 Sep;28(9):1101-1111. doi: 10.1016/j.jsps.2020.07.011. Epub 2020 Aug 03. PMID: 32922141; PMCID: PMC7474170.
Copy Download .nbib Format: NLM
COVID-19 and how evidence of a new disease evolves.

Annals of the rheumatic diseases

Kroon FPB, Mikuls TR, Landewé RB.
PMID: 32796046
Ann Rheum Dis. 2020 Aug 12; doi: 10.1136/annrheumdis-2020-218483. Epub 2020 Aug 12.

No abstract available.

Cite
Kroon FPB, Mikuls TR, Landewé RB. COVID-19 and how evidence of a new disease evolves. Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218483.
Kroon, F. P. B., Mikuls, T. R., & Landewé, R. B. (2020). COVID-19 and how evidence of a new disease evolves. Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218483
Kroon, Féline P B, et al. "COVID-19 and how evidence of a new disease evolves." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218483
Kroon FPB, Mikuls TR, Landewé RB. COVID-19 and how evidence of a new disease evolves. Ann Rheum Dis. 2020 Aug 12; doi: 10.1136/annrheumdis-2020-218483. Epub 2020 Aug 12. PMID: 32796046.
Copy Download .nbib Format: NLM
Immunoglobulin deficiencies in treated patients suffering from rheumatoid arthritis.

Rheumatology international

Kaestner S, Wolff HJ, Braeuer R, Kaestner P.
PMID: 33914121
Rheumatol Int. 2021 Jul;41(7):1273-1280. doi: 10.1007/s00296-021-04871-x. Epub 2021 Apr 29.

Immunoglobulins and antibodies to immunoglobulins (autoimmunoglobulins) have been identified to be implicated in the pathogenesis of rheumatoid arthritis (RA). Immunoglobulin deficiencies have been suggested to account for the increased risk of infections in RA patients. This study was carried...

Cite
Kaestner S, Wolff HJ, Braeuer R, et al. Immunoglobulin deficiencies in treated patients suffering from rheumatoid arthritis. Rheumatol Int. 2021;41(7):1273-1280doi: 10.1007/s00296-021-04871-x.
Kaestner, S., Wolff, H. J., Braeuer, R., & Kaestner, P. (2021). Immunoglobulin deficiencies in treated patients suffering from rheumatoid arthritis. Rheumatology international, 41(7), 1273-1280. https://doi.org/10.1007/s00296-021-04871-x
Kaestner, Sara, et al. "Immunoglobulin deficiencies in treated patients suffering from rheumatoid arthritis." Rheumatology international vol. 41,7 (2021): 1273-1280. doi: https://doi.org/10.1007/s00296-021-04871-x
Kaestner S, Wolff HJ, Braeuer R, Kaestner P. Immunoglobulin deficiencies in treated patients suffering from rheumatoid arthritis. Rheumatol Int. 2021 Jul;41(7):1273-1280. doi: 10.1007/s00296-021-04871-x. Epub 2021 Apr 29. PMID: 33914121.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 120 entries